Western blot shows recombinant HIV Gag p24 (5 ng/lane). PVDF membrane was probed with 2 µg/mL of Mouse Anti-Viral HIV-1 Gag p24 Monoclonal Antibody (Catalog # MAB7360) followed by HRP-conjugated Anti-Mouse IgG ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Sterile PBS to a final concentration of 0.5 mg/mL.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for HIV-1 Gag p24 Antibody (749140) [Unconjugated]
HIV1 Gag p24
HIV-1 Gag p24
The gag gene of human immunodeficiency
virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The
viral protease PR cleaves this precursor to generate p17, p24, p7, and p6
proteins which are required for virus particle assembly. p24 is a major viral
core structural protein. Its measurement is commonly used as an indicator of HIV-1
infection and viral load.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Publications for HIV-1 Gag p24 Antibody (MAB7360)(1)
We have publications tested in 1 confirmed species: Human.
We have publications tested in 1 application: Western Blot.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our HIV-1 Gag p24 Antibody (749140) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.